National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2027
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NIH NCI
Contract Value
Not provided
Codes & Classification
Solicitation Number
75N91026R00109
NAICS
-
Classification Code
AN12
Additional Details
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services, has announced a presolicitation for the Small Business Innovation Research (SBIR) Innovative Concept Award Program for Fiscal Year 2027. This initiative is designed to engage small business concerns in the development of highly innovative and potentially transformative technologies aimed at addressing critical challenges in pediatric and rare cancers.
Purpose and Scope:
The primary objective of this procurement is to support early-stage research and development activities that demonstrate technical feasibility and proof-of-concept for new technologies. The program specifically targets two key areas:
1. The development of therapeutic or preventative technologies for the treatment or prevention of pediatric cancers and/or rare cancers.
2. The development of devices, diagnostic technologies, or digital health tools for the treatment, detection, and diagnosis of pediatric cancers and/or rare cancers.
For the purposes of this solicitation, rare cancers are defined in accordance with the U.S. Food and Drug Administration (FDA) Orphan Drug Act as malignancies with a total U.S. prevalence of fewer than 200,000 individuals. The NCI encourages proposals focused on rare cancers with a five-year survival rate of less than 50%, referencing authoritative data sources such as the SEER database for prevalence and survival statistics.
Key Requirements and Expected Deliverables:
Offerors are not required to provide preliminary data; however, proposals must be grounded in a sound scientific premise, supported by either the offeror’s own research or existing literature. Each proposal should:
- Clearly identify the clinical problem and specific cancer type(s) being addressed, with adequate justification.
- Specify the anticipated product to be developed and outline a clear development pathway.
- Propose experiments designed to obtain initial de-risking and proof-of-concept data.
- Include plans to enhance entrepreneurial skills, develop or refine a business model, and create a commercialization plan.
The program is intended to serve as a pipeline for the federal SBIR program, fostering the translation of innovative concepts into viable commercial products that can improve outcomes for patients with pediatric and rare cancers.
Contracting Entity and Contact Information:
The contracting entity for this opportunity is the NIH NCI, classified as a federal office. The primary point of contact for inquiries is Kathleen Sears, who can be reached at [email protected].
Procurement Type and Set-Aside:
This is a total small business set-aside solicitation under the SBA’s SBIR program. Only eligible small businesses—defined as those with no more than 500 employees, including affiliates—may submit proposals. The size standard is established by law for the SBIR program, regardless of the NAICS code. Offerors should consult the SBA’s SBIR/STTR Policy Directive for additional eligibility requirements.
Additional Details:
- Product Service Code: AN12
- Place of Performance: United States (Country Code: USA)
- Notice Status: Active
- Notice Source: SAM.gov (Opportunity ID: b6f7267813b84393b4b7178dbc9dbd27)
- No attachments or additional documents are currently provided with the notice.
Timeline and Submission:
The formal solicitation is anticipated to be released on or around July 17, 2026, with a closing date expected in late September 2026. Notably, an amendment has clarified that white paper submissions are no longer being requested or accepted under this solicitation. All other terms and conditions remain unchanged.
Additional Resources:
Interested parties are encouraged to explore other SBIR and STTR contract and grant opportunities at https://seed.nih.gov/small-business-funding/find-funding and to review general information about the NCI SBIR Program at https://sbir.cancer.gov/.
This opportunity is well-suited for small businesses with innovative concepts and a commitment to advancing the treatment, detection, and diagnosis of pediatric and rare cancers. The program emphasizes both scientific rigor and commercial potential, making it ideal for firms seeking to bridge the gap between early-stage research and market-ready solutions.